首页> 外文OA文献 >PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen

【2h】

PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen

机译：先前用含多西他赛治疗的转移性激素难治性前列腺癌患者中卡巴他赛与卡托曲酮的威尼托区的PCN83成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Maran P.R.; Aiello A.; Magrì M.R.; Alberti C.; Visentin E.; Venturini F.; Scroccaro G.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. [J] . Oudard S, Banu E, Beuzeboc P, Journal of Clinical Oncology . 2005,第15期

机译：多中心紫杉醇，雌莫司汀和泼尼松与米托蒽醌加泼尼松两种方案治疗转移性激素难治性前列腺癌的多中心随机II期研究。
2. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial [J] . Beer Tomasz M., Hotte Sebastien J., Saad Fred, The lancet oncology . 2017,第11期

机译：Custirsen（OGX-011）与Cabazitaxel和Prednisone与Cabazitaxel和Prednisone一起联合出来的转移阉割阉割前列腺癌患者（亲和力）：随机，开放标签，国际，第3阶段试验
3. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer [J] . R Collins, R Trowman, G Norman, British Journal of Cancer . 2006,第4期

机译：对多西他赛和米托蒽醌治疗转移性激素难治性前列腺癌的有效性的系统评价
4. The Risk for Secondary Cancers in Patients Treated for Prostate Carcinoma - An Analysis with the Competition Dose Response Model [C] . A. Dasu, I. Toma-Dasu, L. Franzen, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：前列腺癌患者继发癌症的风险-竞争剂量反应模型的分析
5. Emergence of metastatic hormone refractory disease in prostate cancer after anti-androgen therapy. [D] . Lee, Edmund Chun Yu. 2004

机译：抗雄激素治疗后前列腺癌中转移激素难治性疾病的出现。
6. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer [O] . R Collins, R Trowman, G Norman, 2006

机译：多西紫杉醇和米托蒽醌治疗转移性激素难治性前列腺癌的有效性的系统评价
7. PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review [O] . Bektur C., Nurgozhin T. 2014

机译：PCN14紫杉醇与阿比特龙对多西他赛治疗后进展的转移性激素-难治性前列腺癌（MHRPC）患者的二线治疗的药物经济学评价：系统评价

PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen

著录项

引文网络

相似文献

相关主题

期刊订阅